Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog
Dr. Anton Yuryev

Dr. Anton Yuryev

Professional Services Director

Connect with Dr. Anton Yuryev on LinkedIn
Website:

About the author:

Dr. Anton Yuryev has M.S degree in Physics from Moscow Institute of Physics and Technology, Russia and Ph.D in Genetics and Molecular Biology from Johns Hopkins University, USA where he discovered proteins physically linking gene transcription with mRNA processing in eukaryotic cells.  He has over 20 years of experience in bioinformatics.  After finishing his post-doctoral training at Novartis Inc Dr. Yuryev worked as Senior Scientist at InforMax, then continued at Orchid Bioscience as Senior Bioinformatics Analyst, and then as Senior Director of Application Science at Ariadne Genomics where he participated in the development of natural language processing technology and award-winning Pathway Studio software.  Dr. Yuryev has published more than 40 scientific publications, edited three scientific books, and authored several algorithms for primer design and pathway analysis.  He works now as Professional Services Director at Elsevier and responsible for development of targeted bioinformatics solutions using Elsevier software and knowledge bases for areas of drug development, personalized medicine and agrobiology.


Posts by Dr. Anton Yuryev

Precise Medicines: Matching Patients with the Most Effective Drugs

Posted on July 14th, 2017 in Pharma R&D

Precision medicine is making us re-think the way we treat disease. Rather than selecting therapies based solely on the disease itself, doctors are increasingly considering the patient’s unique genomic and molecular make-up when determining treatment. Continue reading “Precise Medicines: Matching Patients with the Most Effective Drugs” »

Personalized vs. Precision Medicine

Posted on February 3rd, 2017 in Pharma R&D

Last year was a year of impetus for precision medicine. Former President Obama’s budget for the 2016 fiscal year included $215 million for the National Institutes of Health (NIH), Continue reading “Personalized vs. Precision Medicine” »

The Success of Personalized Anti-Cancer Therapies

Posted on January 4th, 2017 in Pharma R&D

Every day, thousands of cancer patients face difficult choices about their treatment options. For those affected by advanced, stage 4 cancer, the decisions can be particularly painful. Continue reading “The Success of Personalized Anti-Cancer Therapies” »